• Veradermics reported positive topline Phase 2 results from open-label Study 207 of oral extended-release minoxidil VDPHL01 in female pattern hair loss.
• Non-vellus target area hair count rose 22.7 hairs/cm² with 4.5 mg once daily, 23.3 hairs/cm² with 4.5 mg twice daily at Month 6.
• AAIRS patient-reported hair coverage improved in 88.9% of once-daily patients, 90% of twice-daily patients at Month 6.
• Safety profile showed no treatment-related serious adverse events, no cardiac adverse events of special interest.
• Topline results for registration-directed Phase 2/3 Study 306 in female pattern hair loss targeted for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001827635-26-000023), on July 15, 2026, and is solely responsible for the information contained therein.